SCHEMBL3452379

SCHEMBL3452379

CC(C)c1ccccc1-c1csc(C(N)c2cccs2)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP1 O94782 1/20 0.35
WDR48 Q8TAF3 1/20 0.35
HSD17B10 Q99714 3/20 0.33
MPL P40238 1/20 0.33
ATR Q13535 1/20 0.32
PLAU P00749 1/20 0.32
NPC1 O15118 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
DHFR P00374 1/20 0.31
ATP4A P20648 2/20 0.31
ATP4B P51164 2/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3515545 0.78 ALDH1A1 (0.49) HSD17B10NPC1CYP3A4ATP4AATP4B
SCHEMBL3453051 0.78 MAPT (0.37) HSD17B10NPC1KDM4EMEN1ALDH1A1
SCHEMBL23364703 0.74 HSD17B10 (0.57) HSD17B10MPLNPC1CYP1A2CYP3A4
SCHEMBL29932854 0.74 HSD17B10 (0.57) HSD17B10MPLNPC1CYP1A2CYP3A4
SCHEMBL3452382 0.68 USP1 (0.56) USP1WDR48HSD17B10NPC1CYP1A2
SCHEMBL24696014 0.65 ATP4A (0.51) HSD17B10MPLNPC1CYP1A2CYP3A4
SCHEMBL9359646 0.65 ESR1 (0.39) ALOX5MEN1ALDH1A1KMT2A
SCHEMBL10052161 0.64 RAB9A (0.44) HSD17B10MPLNPC1CYP3A4KDM4E
SCHEMBL24696020 0.64 HSD17B10 (0.60) HSD17B10MPLNPC1ATP4AATP4B
SCHEMBL12591900 0.64 MPL (0.60) MPLNPC1CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820704-B2 Substituted heteroaryl derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
EP-1753735-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS Transtech Pharma, Inc. (US) 2007-02-21 EP disclosed
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use VTVX HOLDINGS I LLC 2005-11-24 US disclosed
WO-2005103022-A1 SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS TRANSTECH PHARMA, INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261294-A1 Substituted heteroaryl derivatives, compositions, and methods of use MC5R, MC3R, MC4R USP1 4798/4885WDR48 1088/4885HSD17B10 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.